Metoclopramide its central toxicities Extrapyramidal Side Effects/Dyst

Metoclopramide its central toxicities (Extrapyramidal Side Effects/Dystonia in children) , and why Domperidone is preferred in Parkinson's patients taking Levodopa. Make into flowchart

Reading File

Finding Sources

Reading File

Running Command

ls -la /home/daytona/workspace/ 2>/dev/null | head -20

Running Command

mkdir -p /home/daytona/workspace/metoclopramide-flowchart

Writing File

~/metoclopramide-flowchart/flowchart.html

<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Metoclopramide vs Domperidone Flowchart</title>
<style>
  * { box-sizing: border-box; margin: 0; padding: 0; }
  body {
    font-family: 'Segoe UI', Arial, sans-serif;
    background: #f0f4f8;
    padding: 30px 20px;
  }
  .page-title {
    text-align: center;
    font-size: 22px;
    font-weight: 800;
    color: #1a2a4a;
    margin-bottom: 6px;
    letter-spacing: 0.5px;
  }
  .page-sub {
    text-align: center;
    font-size: 13px;
    color: #5a6a80;
    margin-bottom: 30px;
  }
  .chart-wrapper {
    max-width: 980px;
    margin: 0 auto;
  }

  /* ====== COLUMNS ====== */
  .columns {
    display: flex;
    gap: 0;
    align-items: flex-start;
  }
  .col {
    flex: 1;
    display: flex;
    flex-direction: column;
    align-items: center;
  }
  .col-divider {
    width: 3px;
    background: linear-gradient(180deg, #c0cfe0 0%, #8aaac8 50%, #c0cfe0 100%);
    align-self: stretch;
    margin: 0 8px;
    border-radius: 2px;
  }

  /* ====== BOXES ====== */
  .box {
    width: 100%;
    border-radius: 12px;
    padding: 14px 16px;
    text-align: center;
    position: relative;
    margin-bottom: 0;
  }
  .box-title {
    font-size: 13px;
    font-weight: 700;
    letter-spacing: 0.3px;
    margin-bottom: 4px;
  }
  .box-body {
    font-size: 11.5px;
    line-height: 1.55;
    color: #1a2a4a;
  }
  .box-body ul {
    list-style: none;
    text-align: left;
    padding-left: 4px;
  }
  .box-body ul li::before {
    content: "▸ ";
    color: inherit;
    font-size: 10px;
  }

  /* colour themes */
  .drug-header {
    background: linear-gradient(135deg, #1a3a6e, #2d5fa6);
    color: #fff;
    border-radius: 14px;
    padding: 16px;
    width: 100%;
    text-align: center;
    margin-bottom: 10px;
  }
  .drug-header .drug-name { font-size: 20px; font-weight: 800; letter-spacing: 1px; }
  .drug-header .drug-class { font-size: 11px; opacity: 0.85; margin-top: 3px; }

  .mech { background: #dbeafe; border: 2px solid #93c5fd; }
  .mech .box-title { color: #1e40af; }

  .warning { background: #fee2e2; border: 2px solid #f87171; }
  .warning .box-title { color: #b91c1c; }

  .eps-box { background: #fef3c7; border: 2px solid #f59e0b; }
  .eps-box .box-title { color: #92400e; }

  .dystonia { background: #fde68a; border: 2px solid #d97706; }
  .dystonia .box-title { color: #78350f; }

  .tardive { background: #ffe4e6; border: 2px solid #e11d48; }
  .tardive .box-title { color: #9f1239; }

  .rx { background: #dcfce7; border: 2px solid #4ade80; }
  .rx .box-title { color: #166534; }

  .bbb { background: #f3e8ff; border: 2px solid #a855f7; }
  .bbb .box-title { color: #6b21a8; }

  .dom-adv { background: #ecfdf5; border: 2px solid #34d399; }
  .dom-adv .box-title { color: #065f46; }

  .pref { background: linear-gradient(135deg, #064e3b, #047857); color: #fff; border-radius: 12px; }
  .pref .box-title { color: #d1fae5; }
  .pref .box-body { color: #ecfdf5; }

  .caution { background: #fff7ed; border: 2px solid #fb923c; }
  .caution .box-title { color: #9a3412; }

  /* shared header area */
  .start-node {
    background: linear-gradient(135deg, #374151, #1f2937);
    color: #fff;
    border-radius: 24px;
    padding: 12px 24px;
    font-size: 15px;
    font-weight: 700;
    text-align: center;
    width: 90%;
    margin: 0 auto 0 auto;
  }

  /* arrows */
  .arrow {
    width: 100%;
    display: flex;
    flex-direction: column;
    align-items: center;
    padding: 2px 0;
  }
  .arrow-line {
    width: 2px;
    height: 20px;
    background: #64748b;
  }
  .arrow-head {
    width: 0;
    height: 0;
    border-left: 7px solid transparent;
    border-right: 7px solid transparent;
    border-top: 10px solid #64748b;
  }
  .arrow-label {
    font-size: 10px;
    color: #64748b;
    background: #f0f4f8;
    border-radius: 4px;
    padding: 1px 6px;
    margin-bottom: 1px;
    font-weight: 600;
  }

  /* section labels */
  .section-label {
    font-size: 10px;
    font-weight: 700;
    letter-spacing: 1.5px;
    text-transform: uppercase;
    color: #64748b;
    border-top: 1px dashed #94a3b8;
    width: 90%;
    text-align: center;
    padding-top: 6px;
    margin-bottom: 6px;
  }

  /* shared top node */
  .top-row {
    display: flex;
    justify-content: center;
    margin-bottom: 10px;
  }
  .shared-box {
    max-width: 560px;
    width: 100%;
  }

  /* badge */
  .badge {
    display: inline-block;
    font-size: 10px;
    font-weight: 700;
    padding: 2px 8px;
    border-radius: 20px;
    margin: 3px 2px;
    letter-spacing: 0.3px;
  }
  .badge-red { background: #fee2e2; color: #991b1b; }
  .badge-yellow { background: #fef9c3; color: #854d0e; }
  .badge-green { background: #dcfce7; color: #166534; }
  .badge-purple { background: #f3e8ff; color: #6b21a8; }
  .badge-blue { background: #dbeafe; color: #1e40af; }

  /* footnote */
  .footnote {
    font-size: 10.5px;
    color: #6b7280;
    text-align: center;
    margin-top: 24px;
    border-top: 1px solid #cbd5e1;
    padding-top: 12px;
    line-height: 1.6;
  }

  /* connector between columns at top */
  .top-connector {
    display: flex;
    align-items: center;
    justify-content: center;
    margin-bottom: 10px;
    gap: 0;
    width: 100%;
  }
  .connector-line {
    flex: 1;
    height: 2px;
    background: #94a3b8;
  }
  .connector-mid {
    font-size: 11px;
    font-weight: 700;
    color: #475569;
    padding: 4px 10px;
    background: #e2e8f0;
    border-radius: 8px;
    white-space: nowrap;
  }

  .vs-badge {
    background: #1e293b;
    color: #f8fafc;
    font-size: 13px;
    font-weight: 800;
    padding: 6px 16px;
    border-radius: 20px;
    margin: 0 auto 12px;
    display: table;
    letter-spacing: 1px;
  }
</style>
</head>
<body>

<div class="chart-wrapper">
  <div class="page-title">Metoclopramide Central Toxicities &amp; Domperidone Preference in Parkinson's</div>
  <div class="page-sub">Pharmacology Flowchart — Sources: Goodman &amp; Gilman, Katzung, Sleisenger &amp; Fordtran</div>

  <!-- SHARED MECHANISM TOP -->
  <div class="top-row">
    <div class="shared-box">
      <div class="start-node">
        Prokinetic / Antiemetic Drug Required
      </div>
      <div class="arrow"><div class="arrow-line"></div><div class="arrow-head"></div></div>
      <div class="box mech">
        <div class="box-title">Shared Mechanism of Action</div>
        <div class="box-body">Both are <b>D2 Dopamine Receptor Antagonists</b><br>
        <ul>
          <li>Block D2 receptors in GI tract → prokinetic effect (gastric emptying ↑)</li>
          <li>Block D2 in Chemoreceptor Trigger Zone (CTZ) → antiemetic effect</li>
          <li>CTZ lies outside the blood-brain barrier (area postrema)</li>
        </ul>
        </div>
      </div>
    </div>
  </div>

  <div class="vs-badge">VS</div>

  <!-- TWO COLUMN SECTION -->
  <div class="columns">

    <!-- ===== LEFT: METOCLOPRAMIDE ===== -->
    <div class="col">
      <div class="drug-header">
        <div class="drug-name">METOCLOPRAMIDE</div>
        <div class="drug-class">Substituted Benzamide | D2 + 5-HT3 + 5-HT4</div>
      </div>

      <!-- BBB -->
      <div class="section-label">Blood-Brain Barrier</div>
      <div class="box warning">
        <div class="box-title">⚠ CROSSES the Blood-Brain Barrier</div>
        <div class="box-body">
          Small lipophilic molecule → freely enters CNS<br>
          Blocks <b>central D2 receptors</b> in basal ganglia &amp; nigrostriatal pathway
        </div>
      </div>

      <div class="arrow"><div class="arrow-line"></div><div class="arrow-head"></div></div>

      <!-- EPS mechanism -->
      <div class="box eps-box">
        <div class="box-title">Mechanism of Extrapyramidal Side Effects (EPS)</div>
        <div class="box-body">
          Dopamine blockade in <b>striatum / basal ganglia</b><br>
          → Disrupts dopamine-acetylcholine balance<br>
          → Relative <b>cholinergic excess</b><br>
          → Loss of fine motor control / movement disorders
        </div>
      </div>

      <div class="arrow"><div class="arrow-line"></div><div class="arrow-head"></div></div>

      <!-- Types of EPS -->
      <div class="section-label">Types of EPS (Spectrum)</div>

      <div class="box dystonia" style="margin-bottom:8px;">
        <div class="box-title">1. Acute Dystonia — especially in CHILDREN</div>
        <div class="box-body">
          <ul>
            <li>Onset: minutes–hours after IV dose</li>
            <li>Involuntary sustained muscle contractions</li>
            <li>Oculogyric crisis (eyes roll upward)</li>
            <li>Torticollis (neck twisting), trismus, opisthotonus</li>
            <li><b>Children &amp; young adults most vulnerable</b></li>
            <li>Higher doses → higher risk</li>
            <li>Neonates: also risk of methemoglobinemia</li>
          </ul>
          <br>
          <span class="badge badge-red">High-dose IV risk</span>
          <span class="badge badge-red">Pediatric caution</span>
        </div>
      </div>

      <div class="box eps-box" style="margin-bottom:8px;">
        <div class="box-title">2. Akathisia</div>
        <div class="box-body">
          <ul>
            <li>Subjective restlessness, compulsion to move</li>
            <li>Pacing, inability to sit still</li>
            <li>Can be distressing; often mistaken for anxiety</li>
          </ul>
        </div>
      </div>

      <div class="box eps-box" style="margin-bottom:8px;">
        <div class="box-title">3. Drug-Induced Parkinsonism</div>
        <div class="box-body">
          <ul>
            <li>Weeks after starting therapy</li>
            <li>Tremor, rigidity, bradykinesia</li>
            <li>Reversible on discontinuation</li>
            <li>Elderly most at risk</li>
          </ul>
        </div>
      </div>

      <div class="box tardive" style="margin-bottom:8px;">
        <div class="box-title">4. Tardive Dyskinesia (Chronic Use)</div>
        <div class="box-body">
          <ul>
            <li>Repetitive involuntary movements (lip smacking, tongue protrusion)</li>
            <li>Develops after weeks–months of use</li>
            <li><b>May be IRREVERSIBLE</b></li>
            <li>Risk ↑ in elderly, long-term use</li>
            <li>Long-term use should be <b>avoided</b></li>
          </ul>
          <span class="badge badge-red">Potentially irreversible</span>
        </div>
      </div>

      <div class="arrow"><div class="arrow-line"></div><div class="arrow-head"></div></div>

      <!-- Why children more vulnerable -->
      <div class="box warning">
        <div class="box-title">Why are Children Especially Vulnerable to Dystonia?</div>
        <div class="box-body">
          <ul>
            <li>Immature blood-brain barrier → greater CNS drug penetration</li>
            <li>Higher mg/kg dosing relative to body weight</li>
            <li>Developing dopaminergic system more sensitive</li>
            <li>EPS occur in <b>25% at high doses</b>, 5% long-term</li>
            <li>Metoclopramide <b>NOT recommended in children</b> (Goodman &amp; Gilman)</li>
          </ul>
        </div>
      </div>

      <div class="arrow"><div class="arrow-line"></div><div class="arrow-head"></div></div>

      <!-- Treatment of EPS -->
      <div class="box rx">
        <div class="box-title">Treatment of Acute EPS / Dystonia</div>
        <div class="box-body">
          <ul>
            <li><b>Stop metoclopramide</b> immediately</li>
            <li>IV/IM <b>Diphenhydramine</b> (antihistamine) — first line in children</li>
            <li>IV/IM <b>Benztropine</b> (anticholinergic) — adults</li>
            <li><b>Benzodiazepines</b> if severe</li>
            <li>Symptoms usually resolve within 24–48 h</li>
          </ul>
          <span class="badge badge-green">Responds to anticholinergics</span>
        </div>
      </div>

      <!-- Parkinson contraindication -->
      <div class="arrow"><div class="arrow-line"></div><div class="arrow-head"></div></div>
      <div class="box warning">
        <div class="box-title">⛔ AVOID in Parkinson's Patients on Levodopa</div>
        <div class="box-body">
          Crosses BBB → blocks central D2 receptors<br>
          → <b>Directly antagonizes levodopa's therapeutic effect</b><br>
          → Worsens motor symptoms of Parkinson's disease
        </div>
      </div>

    </div><!-- end left col -->

    <div class="col-divider"></div>

    <!-- ===== RIGHT: DOMPERIDONE ===== -->
    <div class="col">
      <div class="drug-header" style="background: linear-gradient(135deg, #065f46, #047857);">
        <div class="drug-name">DOMPERIDONE</div>
        <div class="drug-class">Benzimidazole Derivative | Primarily D2 peripheral</div>
      </div>

      <!-- BBB -->
      <div class="section-label">Blood-Brain Barrier</div>
      <div class="box bbb">
        <div class="box-title">✅ Does NOT Cross the Blood-Brain Barrier</div>
        <div class="box-body">
          Polar, large molecule → poor CNS penetration<br>
          Cannot block central D2 receptors in basal ganglia<br>
          <b>No central EPS / dystonia / parkinsonian effects</b>
        </div>
      </div>

      <div class="arrow"><div class="arrow-line"></div><div class="arrow-head"></div></div>

      <!-- Where it acts -->
      <div class="box dom-adv">
        <div class="box-title">Where Domperidone DOES Act</div>
        <div class="box-body">
          <ul>
            <li><b>Peripheral GI tract</b> — D2 blockade → gastric emptying ↑</li>
            <li><b>Area Postrema (CTZ)</b> — lies outside BBB → antiemetic</li>
            <li><b>Pituitary</b> — also outside BBB → ↑ prolactin (galactorrhea risk)</li>
          </ul>
          <br>
          <span class="badge badge-green">Peripheral action only</span>
          <span class="badge badge-purple">CTZ accessible</span>
        </div>
      </div>

      <div class="arrow"><div class="arrow-line"></div><div class="arrow-head"></div></div>

      <!-- EPS comparison -->
      <div class="box dom-adv">
        <div class="box-title">Extrapyramidal Side Effects</div>
        <div class="box-body">
          <ul>
            <li>CNS EPS (dystonia, akathisia, tardive dyskinesia): <b>RARE</b></li>
            <li>No drug-induced parkinsonism</li>
            <li>No worsening of existing movement disorders</li>
            <li>"Extremely well tolerated" — Katzung</li>
          </ul>
          <span class="badge badge-green">No CNS EPS</span>
        </div>
      </div>

      <div class="arrow"><div class="arrow-line"></div><div class="arrow-head"></div></div>

      <!-- Parkinson's section -->
      <div class="section-label">Parkinson's Disease + Levodopa Context</div>

      <div class="box bbb" style="margin-bottom:8px;">
        <div class="box-title">Problem: Nausea in Parkinson's Patients</div>
        <div class="box-body">
          <ul>
            <li>Levodopa itself causes nausea &amp; vomiting</li>
            <li>Delayed gastric emptying reduces levodopa absorption → poor motor control</li>
            <li>Parkinson's disease itself → gastric dysmotility</li>
            <li>Patient needs an antiemetic/prokinetic</li>
          </ul>
        </div>
      </div>

      <div class="arrow">
        <div class="arrow-label">Why not metoclopramide?</div>
        <div class="arrow-line"></div>
        <div class="arrow-head"></div>
      </div>

      <div class="box pref">
        <div class="box-title">✅ WHY DOMPERIDONE IS PREFERRED</div>
        <div class="box-body">
          <ul>
            <li>Blocks D2 in CTZ &amp; gut → relieves levodopa-induced nausea ✓</li>
            <li>Improves gastric emptying → better levodopa absorption ✓</li>
            <li>Does NOT cross BBB → does NOT block striatal D2 ✓</li>
            <li>Levodopa's therapeutic effect in the brain is <b>preserved</b> ✓</li>
            <li>No worsening of parkinsonian motor symptoms ✓</li>
          </ul>
        </div>
      </div>

      <div class="arrow"><div class="arrow-line"></div><div class="arrow-head"></div></div>

      <!-- Summary advantage -->
      <div class="box dom-adv">
        <div class="box-title">Clinical Summary: Domperidone's Key Advantage</div>
        <div class="box-body">
          Antagonizes the <b>pro-emetic peripheral effects</b> of levodopa<br>
          <i>without</i> interfering with its <b>anti-parkinsonian central action</b><br>
          — Sleisenger &amp; Fordtran's GI Disease
        </div>
      </div>

      <div class="arrow"><div class="arrow-line"></div><div class="arrow-head"></div></div>

      <!-- Caution -->
      <div class="box caution">
        <div class="box-title">⚠ Domperidone Cautions</div>
        <div class="box-body">
          <ul>
            <li><b>QT prolongation</b> → risk of ventricular arrhythmia / sudden death</li>
            <li>Risk ↑ in age &gt;60 years &amp; doses &gt;30 mg/day</li>
            <li>Not available in USA (FDA expanded access only)</li>
            <li>Prolactin ↑ → galactorrhea, gynecomastia, amenorrhea</li>
          </ul>
          <span class="badge badge-yellow">Cardiac monitoring advised</span>
        </div>
      </div>

    </div><!-- end right col -->
  </div><!-- end columns -->

  <!-- BOTTOM COMPARISON TABLE -->
  <div style="margin-top: 28px; overflow-x:auto;">
    <table style="width:100%; border-collapse: collapse; font-size:12px; background:#fff; border-radius:12px; overflow:hidden; box-shadow: 0 2px 8px rgba(0,0,0,0.08);">
      <thead>
        <tr style="background:#1e3a5f; color:#fff;">
          <th style="padding:10px 14px; text-align:left;">Property</th>
          <th style="padding:10px 14px; text-align:center;">Metoclopramide</th>
          <th style="padding:10px 14px; text-align:center;">Domperidone</th>
        </tr>
      </thead>
      <tbody>
        <tr style="background:#f8fafc;"><td style="padding:8px 14px; font-weight:600;">Class</td><td style="text-align:center; padding:8px;">Substituted benzamide</td><td style="text-align:center; padding:8px;">Benzimidazole derivative</td></tr>
        <tr><td style="padding:8px 14px; font-weight:600;">Receptor</td><td style="text-align:center; padding:8px;">D2 + 5-HT3 + 5-HT4</td><td style="text-align:center; padding:8px;">D2 (primarily peripheral)</td></tr>
        <tr style="background:#f8fafc;"><td style="padding:8px 14px; font-weight:600;">Crosses BBB?</td><td style="text-align:center; padding:8px; color:#dc2626;"><b>YES</b></td><td style="text-align:center; padding:8px; color:#16a34a;"><b>NO (minimally)</b></td></tr>
        <tr><td style="padding:8px 14px; font-weight:600;">Central EPS risk</td><td style="text-align:center; padding:8px; color:#dc2626;"><b>HIGH (5–25%)</b></td><td style="text-align:center; padding:8px; color:#16a34a;"><b>Rare</b></td></tr>
        <tr style="background:#f8fafc;"><td style="padding:8px 14px; font-weight:600;">Dystonia in children</td><td style="text-align:center; padding:8px; color:#dc2626;"><b>YES — significant risk</b></td><td style="text-align:center; padding:8px; color:#16a34a;">Not significant</td></tr>
        <tr><td style="padding:8px 14px; font-weight:600;">Worsens Parkinson's?</td><td style="text-align:center; padding:8px; color:#dc2626;"><b>YES — blocks striatal D2</b></td><td style="text-align:center; padding:8px; color:#16a34a;"><b>NO</b></td></tr>
        <tr style="background:#f8fafc;"><td style="padding:8px 14px; font-weight:600;">Use with levodopa?</td><td style="text-align:center; padding:8px; color:#dc2626;"><b>CONTRAINDICATED</b></td><td style="text-align:center; padding:8px; color:#16a34a;"><b>PREFERRED</b></td></tr>
        <tr><td style="padding:8px 14px; font-weight:600;">QT prolongation</td><td style="text-align:center; padding:8px;">Yes (moderate)</td><td style="text-align:center; padding:8px; color:#d97706;">Yes (significant, esp. elderly)</td></tr>
        <tr style="background:#f8fafc;"><td style="padding:8px 14px; font-weight:600;">Prolactin elevation</td><td style="text-align:center; padding:8px;">Yes</td><td style="text-align:center; padding:8px;">Yes</td></tr>
        <tr><td style="padding:8px 14px; font-weight:600;">Use in children</td><td style="text-align:center; padding:8px; color:#dc2626;">Not recommended</td><td style="text-align:center; padding:8px; color:#d97706;">Limited evidence</td></tr>
        <tr style="background:#f8fafc;"><td style="padding:8px 14px; font-weight:600;">US availability</td><td style="text-align:center; padding:8px; color:#16a34a;">Yes (FDA approved)</td><td style="text-align:center; padding:8px; color:#dc2626;">Expanded access only</td></tr>
      </tbody>
    </table>
  </div>

  <div class="footnote">
    Sources: Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics | Katzung's Basic &amp; Clinical Pharmacology 16e | Sleisenger &amp; Fordtran's GI &amp; Liver Disease | Yamada's Textbook of Gastroenterology<br>
    EPS = Extrapyramidal Side Effects | BBB = Blood-Brain Barrier | CTZ = Chemoreceptor Trigger Zone | D2 = Dopamine D2 Receptor
  </div>
</div>

</body>
</html>

Running Command

cd /home/daytona/workspace/metoclopramide-flowchart && chromium --headless --no-sandbox --disable-gpu --print-to-pdf=flowchart.pdf --print-to-pdf-no-header --virtual-time-budget=3000 flowchart.html 2>&1 && ls -lh flowchart.pdf

Both files are ready. Here's the complete answer with the flowchart:

Metoclopramide Central Toxicities & Domperidone Preference in Parkinson's

Download your flowchart here:

flowchart
HTML File · HTML
- interactive, best for viewing in browser
flowchart
PDF Document · PDF
- printable PDF

Flowchart Summary (Text Version)

Shared Starting Point

Both metoclopramide and domperidone are D2 dopamine receptor antagonists used as prokinetics/antiemetics. They both block D2 in the Chemoreceptor Trigger Zone (CTZ) - which sits outside the blood-brain barrier in the area postrema - to stop vomiting, and in the GI tract to speed gastric emptying.

METOCLOPRAMIDE Branch

Crosses the BBB (small, lipophilic molecule) ↓ Blocks central D2 receptors in the basal ganglia/striatum ↓ Disrupts dopamine-acetylcholine balance → relative cholinergic excess ↓

4 Types of EPS:

EPS Type	Key Features
1. Acute Dystonia	Oculogyric crisis, torticollis, opisthotonus - minutes to hours post-IV
2. Akathisia	Restlessness, compulsion to pace - often mistaken for anxiety
3. Drug-induced Parkinsonism	Tremor, rigidity, bradykinesia - weeks after starting
4. Tardive Dyskinesia	Lip smacking, tongue protrusion - chronic use, may be irreversible

Why children are especially vulnerable to dystonia:

Immature BBB → greater CNS drug penetration
Higher weight-adjusted dosing
Developing dopaminergic system is more sensitive
EPS occur in 25% at high doses, 5% with long-term use (Katzung 16e)
Neonates also risk methemoglobinemia
Metoclopramide is not recommended in children (Goodman & Gilman)

Treatment of acute dystonia: Stop the drug + IV/IM Diphenhydramine (children) or Benztropine (adults)

Why to AVOID in Parkinson's: Crosses BBB → blocks the same striatal D2 receptors that levodopa is trying to stimulate → directly counteracts therapy.

DOMPERIDONE Branch

Does NOT cross the BBB (polar, large molecule - poor CNS penetration) ↓ Only acts at: peripheral GI tract + area postrema (CTZ) + pituitary ↓ No central EPS, no dystonia, no drug-induced parkinsonism

Why PREFERRED in Parkinson's patients on Levodopa:

Blocks D2 at the CTZ → relieves levodopa-induced nausea ✓
Improves gastric emptying → better levodopa absorption ✓
Cannot reach basal ganglia → does not antagonize levodopa's anti-parkinsonian action ✓
"Antagonizes the pro-emetic peripheral effects of levodopa without interfering with its anti-parkinsonian action in brain centers protected by the blood-brain barrier" - Sleisenger & Fordtran

Domperidone's own cautions: QT prolongation (risk of ventricular arrhythmia, especially age >60 or dose >30 mg/day); prolactin elevation (galactorrhea, gynecomastia); not available in the USA except via FDA expanded access.

Sources: Goodman & Gilman's Pharmacological Basis of Therapeutics | Katzung's Basic & Clinical Pharmacology 16e | Sleisenger & Fordtran's GI and Liver Disease | Yamada's Textbook of Gastroenterology

Metoclopramide its central toxicities (Extrapyramidal Side Effects/Dystonia in children) , and why Domperidone is preferred in Parkinson's patients taking Levodopa. Answer from kdt and make it point wise and Make into flowchart

Finding Sources

Reading File

Finding Sources

Writing File

~/metoclopramide-flowchart/kdt_flowchart.html

<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Metoclopramide – KDT Style Flowchart</title>
<style>
  *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
  body {
    font-family: 'Segoe UI', Arial, sans-serif;
    background: #eef2f7;
    padding: 28px 18px 40px;
    color: #1a2035;
  }

  /* ─── PAGE HEADER ─── */
  .pg-title {
    text-align: center;
    font-size: 21px;
    font-weight: 900;
    color: #0d1b3e;
    letter-spacing: 0.6px;
    margin-bottom: 4px;
  }
  .pg-sub {
    text-align: center;
    font-size: 12px;
    color: #5c6b82;
    margin-bottom: 26px;
  }

  /* ─── LAYOUT ─── */
  .wrapper { max-width: 1020px; margin: 0 auto; }

  /* ─── ARROW ─── */
  .arr {
    display: flex;
    flex-direction: column;
    align-items: center;
    margin: 0 auto;
    width: 20px;
  }
  .arr-line { width: 2px; height: 22px; background: #5a7190; }
  .arr-head {
    width: 0; height: 0;
    border-left: 8px solid transparent;
    border-right: 8px solid transparent;
    border-top: 12px solid #5a7190;
  }
  .arr-lbl {
    font-size: 10px; font-weight: 700; color: #5a7190;
    background: #eef2f7; padding: 1px 8px;
    border-radius: 4px; margin-bottom: 2px;
    white-space: nowrap;
  }

  /* wide arr for full-width sections */
  .arr-wide {
    display: flex; flex-direction: column; align-items: center;
    margin: 6px auto; width: 100%;
  }

  /* ─── GENERIC BOX ─── */
  .box {
    border-radius: 10px;
    padding: 13px 16px;
    margin-bottom: 0;
    width: 100%;
  }
  .box-h {
    font-size: 13px; font-weight: 800;
    margin-bottom: 7px;
    letter-spacing: 0.3px;
  }
  .box ul { padding-left: 18px; }
  .box li { font-size: 12px; line-height: 1.65; margin-bottom: 2px; }
  .box li::marker { font-size: 10px; }
  .note { font-size: 11px; font-style: italic; color: #4a5568; margin-top: 6px; }

  /* ─── COLOUR THEMES ─── */
  .c-drug  { background:#0d3466; color:#fff; border-radius:14px; text-align:center; padding:15px 20px; }
  .c-drug .big { font-size:22px; font-weight:900; letter-spacing:1.5px; }
  .c-drug .sm  { font-size:11.5px; opacity:.85; margin-top:3px; }

  .c-dom-drug { background:#044a35; color:#fff; border-radius:14px; text-align:center; padding:15px 20px; }
  .c-dom-drug .big { font-size:22px; font-weight:900; letter-spacing:1.5px; }
  .c-dom-drug .sm  { font-size:11.5px; opacity:.85; margin-top:3px; }

  .c-shared { background:#dbeafe; border:2px solid #93c5fd; }
  .c-shared .box-h { color:#1d4ed8; }

  .c-mech   { background:#e0f2fe; border:2px solid #38bdf8; }
  .c-mech   .box-h { color:#0369a1; }

  .c-warn   { background:#fee2e2; border:2px solid #f87171; }
  .c-warn   .box-h { color:#b91c1c; }

  .c-eps    { background:#fff3cd; border:2px solid #f59e0b; }
  .c-eps    .box-h { color:#92400e; }

  .c-d1     { background:#fde68a; border:2px solid #d97706; }
  .c-d1     .box-h { color:#78350f; }

  .c-d2     { background:#ffe4e6; border:2px solid #f43f5e; }
  .c-d2     .box-h { color:#9f1239; }

  .c-rx     { background:#d1fae5; border:2px solid #34d399; }
  .c-rx     .box-h { color:#065f46; }

  .c-bbb    { background:#ede9fe; border:2px solid #8b5cf6; }
  .c-bbb    .box-h { color:#5b21b6; }

  .c-dom    { background:#ecfdf5; border:2px solid #10b981; }
  .c-dom    .box-h { color:#047857; }

  .c-pref   { background:#064e3b; color:#ecfdf5; border-radius:10px; }
  .c-pref   .box-h { color:#6ee7b7; }
  .c-pref li { color:#ecfdf5; }

  .c-caut   { background:#fff7ed; border:2px solid #fb923c; }
  .c-caut   .box-h { color:#9a3412; }

  .c-ci     { background:#fee2e2; border:2px solid #dc2626; }
  .c-ci     .box-h { color:#991b1b; }

  /* ─── BADGE ─── */
  .badge {
    display: inline-block; font-size: 10px; font-weight: 700;
    padding: 2px 9px; border-radius: 20px; margin: 3px 3px 0 0;
  }
  .b-red    { background:#fee2e2; color:#991b1b; }
  .b-green  { background:#dcfce7; color:#166534; }
  .b-yellow { background:#fef9c3; color:#854d0e; }
  .b-purple { background:#f3e8ff; color:#6b21a8; }
  .b-blue   { background:#dbeafe; color:#1e40af; }
  .b-white  { background:rgba(255,255,255,0.2); color:#fff; }

  /* ─── VS divider ─── */
  .vs-bar {
    display:flex; align-items:center; gap:14px;
    margin: 20px 0 16px;
  }
  .vs-bar .line { flex:1; height:2px; background:#94a3b8; }
  .vs-bar .vs   { font-size:14px; font-weight:900; color:#f8fafc;
                  background:#1e293b; padding:6px 18px; border-radius:20px; }

  /* ─── GRID 2-col ─── */
  .grid2 { display:grid; grid-template-columns:1fr 4px 1fr; gap:0 0; }
  .col-l { display:flex; flex-direction:column; align-items:center; gap:8px; padding-right:10px; }
  .col-r { display:flex; flex-direction:column; align-items:center; gap:8px; padding-left:10px; }
  .vdiv  {
    background: linear-gradient(180deg,#c0cfe0,#8aaac8,#c0cfe0);
    border-radius:2px; align-self:stretch;
  }

  /* ─── TABLE ─── */
  .comp-table { width:100%; border-collapse:collapse; font-size:12px; margin-top:24px;
                border-radius:12px; overflow:hidden;
                box-shadow:0 2px 10px rgba(0,0,0,.1); }
  .comp-table thead tr { background:#0d3466; color:#fff; }
  .comp-table th, .comp-table td { padding:9px 13px; text-align:left; vertical-align:top; }
  .comp-table tbody tr:nth-child(even) { background:#f1f5fb; }
  .comp-table tbody tr:nth-child(odd)  { background:#fff; }
  .comp-table td:first-child { font-weight:700; color:#1e3a5f; }
  .tick  { color:#16a34a; font-weight:800; }
  .cross { color:#dc2626; font-weight:800; }

  /* ─── SECTION LABEL ─── */
  .sec-lbl {
    font-size:10px; font-weight:800; letter-spacing:1.8px;
    text-transform:uppercase; color:#64748b;
    border-top:1px dashed #94a3b8;
    padding-top:6px; text-align:center; width:90%;
  }

  /* ─── KEY BOX (shared top) ─── */
  .key-wrap { max-width:600px; margin:0 auto; display:flex; flex-direction:column; align-items:center; }

  /* footnote */
  .fn { font-size:10.5px; color:#64748b; text-align:center;
        border-top:1px solid #cbd5e1; padding-top:12px; margin-top:22px; line-height:1.7; }

  /* EPS numbered cards */
  .eps-grid { display:grid; grid-template-columns:1fr 1fr; gap:8px; width:100%; }
  .eps-card { border-radius:8px; padding:10px 12px; }
  .eps-card .ec-h { font-size:11.5px; font-weight:800; margin-bottom:5px; }
  .eps-card ul { padding-left:14px; }
  .eps-card li { font-size:11px; line-height:1.55; }

  .ec-acute  { background:#fde68a; border:2px solid #d97706; }
  .ec-acute  .ec-h { color:#78350f; }
  .ec-akath  { background:#fff3cd; border:2px solid #f59e0b; }
  .ec-akath  .ec-h { color:#92400e; }
  .ec-park   { background:#ffe4e6; border:2px solid #f87171; }
  .ec-park   .ec-h { color:#b91c1c; }
  .ec-tard   { background:#fecaca; border:2px solid #dc2626; }
  .ec-tard   .ec-h { color:#7f1d1d; }
</style>
</head>
<body>
<div class="wrapper">

  <!-- TITLE -->
  <div class="pg-title">Metoclopramide — Central Toxicities, EPS &amp; Domperidone Preference in Parkinson's</div>
  <div class="pg-sub">Point-wise Pharmacology Flowchart | Sources: Katzung 16e · Goodman &amp; Gilman · Lippincott Pharmacology (KDT-equivalent)</div>

  <!-- ══════════════════════════════════════════
       SHARED MECHANISM
  ══════════════════════════════════════════ -->
  <div class="key-wrap">
    <div class="box c-shared" style="text-align:center; padding:14px 20px;">
      <div class="box-h" style="font-size:14px;">Prokinetic / Antiemetic Needed</div>
      <div style="font-size:12px; color:#374151;">
        Both drugs are <b>Dopamine D2 Receptor Antagonists</b> — used as prokinetics &amp; antiemetics
      </div>
    </div>

    <div class="arr-wide">
      <div class="arr"><div class="arr-line"></div><div class="arr-head"></div></div>
    </div>

    <div class="box c-mech" style="width:100%;">
      <div class="box-h">Shared Mechanism (KDT basis)</div>
      <ul>
        <li>Block <b>D2 receptors in GI tract</b> → remove dopaminergic inhibition of ACh → coordinated peristalsis ↑ → gastric emptying ↑</li>
        <li>Block <b>D2 in Chemoreceptor Trigger Zone (CTZ) / area postrema</b> → potent antiemetic action</li>
        <li>CTZ lies <b>outside the blood-brain barrier (BBB)</b> — accessible to both drugs</li>
        <li>Metoclopramide additionally: 5-HT4 agonist, 5-HT3 antagonist, sensitises muscarinic receptors</li>
      </ul>
    </div>
  </div>

  <!-- VS BAR -->
  <div class="vs-bar"><div class="line"></div><div class="vs">VS</div><div class="line"></div></div>

  <!-- ══════════════════════════════════════════
       TWO-COLUMN
  ══════════════════════════════════════════ -->
  <div class="grid2">

    <!-- ══ LEFT — METOCLOPRAMIDE ══ -->
    <div class="col-l">

      <div class="c-drug box" style="width:100%;">
        <div class="big">METOCLOPRAMIDE</div>
        <div class="sm">Substituted Benzamide | D2 + 5-HT3 antagonist + 5-HT4 agonist</div>
        <div style="margin-top:8px;">
          <span class="badge b-white">t½ 4–6 h</span>
          <span class="badge b-white">Oral / IV / IM / SC</span>
          <span class="badge b-white">Dose: 10 mg TDS</span>
        </div>
      </div>

      <!-- BBB -->
      <div class="sec-lbl">Step 1 — Blood-Brain Barrier</div>
      <div class="box c-warn" style="width:100%;">
        <div class="box-h">⚠ FREELY CROSSES the Blood-Brain Barrier</div>
        <ul>
          <li>Small, lipophilic molecule → unrestricted CNS entry</li>
          <li>Blocks <b>central D2 receptors</b> in the <b>basal ganglia / nigrostriatal pathway</b></li>
          <li>This is the root cause of all central toxicities</li>
        </ul>
      </div>

      <!-- Mechanism of EPS -->
      <div class="arr"><div class="arr-line"></div><div class="arr-head"></div></div>
      <div class="sec-lbl">Step 2 — Mechanism of EPS</div>
      <div class="box c-eps" style="width:100%;">
        <div class="box-h">How EPS Occurs — Point-wise</div>
        <ul>
          <li>Dopamine normally <b>inhibits</b> acetylcholine release in the striatum</li>
          <li>D2 blockade → <b>relative ACh excess</b> (dopamine-ACh imbalance)</li>
          <li>Leads to <b>disinhibition of excitatory pathways</b> in basal ganglia</li>
          <li>Result: abnormal, involuntary movement patterns → EPS</li>
          <li>EPS frequency: <b>25% at high doses</b>, <b>5% with long-term therapy</b> (Katzung)</li>
        </ul>
      </div>

      <!-- EPS spectrum -->
      <div class="arr"><div class="arr-line"></div><div class="arr-head"></div></div>
      <div class="sec-lbl">Step 3 — Spectrum of EPS (4 Types)</div>
      <div class="eps-grid">

        <div class="eps-card ec-acute">
          <div class="ec-h">1. Acute Dystonia ★ (esp. children)</div>
          <ul>
            <li>Onset: <b>minutes–hours</b> after IV dose</li>
            <li>Sustained involuntary muscle contractions</li>
            <li><b>Oculogyric crisis</b> (eyes deviate upward)</li>
            <li><b>Torticollis</b> (neck twisting)</li>
            <li><b>Trismus</b>, opisthotonus</li>
            <li>Laryngospasm (rare, dangerous)</li>
          </ul>
        </div>

        <div class="eps-card ec-akath">
          <div class="ec-h">2. Akathisia</div>
          <ul>
            <li>Onset: hours–days</li>
            <li>Inner restlessness, urge to move</li>
            <li>Pacing, inability to sit still</li>
            <li>Often mistaken for anxiety</li>
            <li>Treated with propranolol or benzodiazepines</li>
          </ul>
        </div>

        <div class="eps-card ec-park">
          <div class="ec-h">3. Drug-Induced Parkinsonism</div>
          <ul>
            <li>Onset: <b>weeks after starting</b></li>
            <li>Tremor, rigidity, bradykinesia, mask-like face</li>
            <li>Reversible on stopping the drug</li>
            <li>Most common in elderly</li>
          </ul>
        </div>

        <div class="eps-card ec-tard">
          <div class="ec-h">4. Tardive Dyskinesia ⚠</div>
          <ul>
            <li>Onset: months–years of chronic use</li>
            <li>Repetitive: lip smacking, tongue protrusion, grimacing</li>
            <li><b>May be IRREVERSIBLE</b></li>
            <li>Long-term use must be avoided</li>
            <li>Elderly at highest risk</li>
          </ul>
        </div>
      </div>

      <!-- Dystonia in children -->
      <div class="arr"><div class="arr-line"></div><div class="arr-head"></div></div>
      <div class="sec-lbl">Step 4 — Why Children Are Most Vulnerable to Dystonia</div>
      <div class="box c-warn" style="width:100%;">
        <div class="box-h">Dystonia in Children — Key Points</div>
        <ul>
          <li><b>Immature BBB</b> → greater CNS penetration of metoclopramide</li>
          <li>Higher <b>mg/kg exposure</b> relative to adult dosing</li>
          <li>Developing dopaminergic system is more sensitive to D2 blockade</li>
          <li>EPS more common in <b>children and young adults</b> at higher doses (Goodman &amp; Gilman)</li>
          <li>Neonates: additional risk of <b>methemoglobinemia</b></li>
          <li>Metoclopramide is <b>NOT recommended in children</b> — significant safety concern</li>
        </ul>
        <div class="note">Exam pearl: Oculogyric crisis after IV metoclopramide in a child = acute dystonic reaction</div>
      </div>

      <!-- Treatment -->
      <div class="arr"><div class="arr-line"></div><div class="arr-head"></div></div>
      <div class="sec-lbl">Step 5 — Treatment of EPS / Acute Dystonia</div>
      <div class="box c-rx" style="width:100%;">
        <div class="box-h">Management — Point-wise</div>
        <ul>
          <li><b>Stop metoclopramide immediately</b></li>
          <li><b>IV/IM Diphenhydramine</b> (antihistamine, 25–50 mg) — first choice in children &amp; emergency</li>
          <li><b>Benztropine</b> (anticholinergic) 1–2 mg IV/IM — adults</li>
          <li><b>Benzodiazepines</b> (diazepam) if severe/unresponsive</li>
          <li>Symptoms resolve within <b>24–48 hours</b></li>
          <li>Tardive dyskinesia may NOT respond and may be irreversible</li>
        </ul>
        <div class="note">Mechanism of antidote: anticholinergics restore dopamine-ACh balance in striatum</div>
      </div>

      <!-- CI in Parkinson -->
      <div class="arr"><div class="arr-line"></div><div class="arr-head"></div></div>
      <div class="box c-ci" style="width:100%;">
        <div class="box-h">⛔ CONTRAINDICATED in Parkinson's + Levodopa</div>
        <ul>
          <li>Crosses BBB → blocks striatal D2 receptors</li>
          <li><b>Directly opposes levodopa's mechanism of action</b></li>
          <li>Worsens motor symptoms (rigidity, tremor, bradykinesia)</li>
          <li>Metoclopramide is <b>contraindicated</b> in Parkinson's disease (Yamada's Gastroenterology)</li>
        </ul>
      </div>

    </div><!-- end left col -->

    <!-- VERTICAL DIVIDER -->
    <div class="vdiv"></div>

    <!-- ══ RIGHT — DOMPERIDONE ══ -->
    <div class="col-r">

      <div class="c-dom-drug box" style="width:100%;">
        <div class="big">DOMPERIDONE</div>
        <div class="sm">Benzimidazole Derivative | Peripheral D2 Antagonist</div>
        <div style="margin-top:8px;">
          <span class="badge b-white">t½ 7 h</span>
          <span class="badge b-white">Oral only (mainly)</span>
          <span class="badge b-white">Dose: 10–20 mg TDS</span>
        </div>
      </div>

      <!-- BBB -->
      <div class="sec-lbl">Step 1 — Blood-Brain Barrier</div>
      <div class="box c-bbb" style="width:100%;">
        <div class="box-h">✅ Does NOT Cross the Blood-Brain Barrier</div>
        <ul>
          <li>Polar, high molecular weight molecule → extremely poor CNS penetration</li>
          <li>Cannot reach the <b>basal ganglia or nigrostriatal pathway</b></li>
          <li>No central D2 blockade → <b>no EPS, no dystonia, no drug-induced parkinsonism</b></li>
          <li>"Neuropsychiatric and extrapyramidal effects are rare" (Katzung 16e)</li>
        </ul>
      </div>

      <!-- Where it acts -->
      <div class="arr"><div class="arr-line"></div><div class="arr-head"></div></div>
      <div class="sec-lbl">Step 2 — Sites of Action (Point-wise)</div>
      <div class="box c-dom" style="width:100%;">
        <div class="box-h">Where Domperidone Acts</div>
        <ul>
          <li><b>GI tract (peripheral D2)</b>: removes dopaminergic inhibition → ACh ↑ → gastric emptying ↑</li>
          <li><b>Area postrema / CTZ</b>: outside BBB → D2 blockade → antiemetic</li>
          <li><b>Pituitary (outside BBB)</b>: blocks dopamine inhibition of prolactin → prolactin ↑ (galactorrhea risk)</li>
          <li><b>Cannot</b> reach striatum, basal ganglia, or cortex</li>
        </ul>
        <span class="badge b-green">Peripheral action</span>
        <span class="badge b-purple">CTZ accessible</span>
        <span class="badge b-yellow">No striatal action</span>
      </div>

      <!-- No EPS -->
      <div class="arr"><div class="arr-line"></div><div class="arr-head"></div></div>
      <div class="box c-dom" style="width:100%;">
        <div class="box-h">EPS Profile (Point-wise)</div>
        <ul>
          <li>Acute dystonia: <b>ABSENT</b></li>
          <li>Akathisia: <b>ABSENT</b></li>
          <li>Drug-induced parkinsonism: <b>ABSENT</b></li>
          <li>Tardive dyskinesia: <b>ABSENT</b></li>
          <li>Safe in children with respect to EPS (though efficacy limited)</li>
          <li><b>"Extremely well tolerated"</b> — Katzung</li>
        </ul>
      </div>

      <!-- Parkinson context -->
      <div class="arr"><div class="arr-line"></div><div class="arr-head"></div></div>
      <div class="sec-lbl">Step 3 — Why Preferred in Parkinson's on Levodopa</div>
      <div class="box c-bbb" style="width:100%;">
        <div class="box-h">The Problem in Parkinson's Patients</div>
        <ul>
          <li>Levodopa itself causes <b>nausea and vomiting</b> (stimulates D2 in CTZ)</li>
          <li>Parkinson's disease → <b>gastroparesis / delayed gastric emptying</b></li>
          <li>Delayed emptying reduces levodopa absorption → <b>poor motor control</b></li>
          <li>Patient needs an antiemetic/prokinetic</li>
          <li>But ordinary antiemetics that cross BBB will <b>worsen Parkinsonism</b></li>
        </ul>
      </div>

      <div class="arr">
        <div class="arr-lbl">Solution →</div>
        <div class="arr-line"></div>
        <div class="arr-head"></div>
      </div>

      <div class="box c-pref" style="width:100%;">
        <div class="box-h" style="font-size:14px;">✅ DOMPERIDONE IS PREFERRED — Reasons (Point-wise)</div>
        <ul>
          <li>Blocks D2 in <b>CTZ</b> → relieves levodopa-induced nausea ✓</li>
          <li>Improves <b>gastric emptying</b> → better &amp; faster levodopa absorption → improved motor function ✓</li>
          <li>Does NOT cross BBB → does NOT block striatal D2 ✓</li>
          <li><b>Levodopa's anti-parkinsonian effect is fully preserved</b> ✓</li>
          <li>No worsening of tremor, rigidity, or bradykinesia ✓</li>
          <li>Antagonises <b>peripheral pro-emetic effects</b> of levodopa without interfering with its <b>central anti-parkinsonian action</b> — (Sleisenger &amp; Fordtran)</li>
        </ul>
      </div>

      <!-- Cautions -->
      <div class="arr"><div class="arr-line"></div><div class="arr-head"></div></div>
      <div class="sec-lbl">Step 4 — Domperidone Adverse Effects / Cautions</div>
      <div class="box c-caut" style="width:100%;">
        <div class="box-h">⚠ Domperidone Cautions (Point-wise)</div>
        <ul>
          <li><b>QT prolongation</b> → risk of <b>ventricular arrhythmia / sudden cardiac death</b></li>
          <li>Risk ↑ in: age &gt;60 years, dose &gt;30 mg/day, concurrent CYP3A4 inhibitors</li>
          <li><b>Prolactin ↑</b> → galactorrhea, gynecomastia, amenorrhea, impotence</li>
          <li>Metabolised by <b>hepatic CYP3A4</b> — drug interactions important</li>
          <li><b>NOT available in USA</b> — FDA expanded access/investigational only</li>
          <li>Available in most other countries (including India, UK, Europe)</li>
        </ul>
        <span class="badge b-yellow">Cardiac monitoring needed</span>
        <span class="badge b-yellow">Avoid &gt;30 mg/day in elderly</span>
      </div>

    </div><!-- end right col -->
  </div><!-- end grid2 -->

  <!-- ══════════════════════════════════════════
       COMPARISON TABLE
  ══════════════════════════════════════════ -->
  <table class="comp-table">
    <thead>
      <tr>
        <th>Feature</th>
        <th>Metoclopramide</th>
        <th>Domperidone</th>
      </tr>
    </thead>
    <tbody>
      <tr><td>Drug class</td><td>Substituted benzamide</td><td>Benzimidazole derivative</td></tr>
      <tr><td>Receptor</td><td>D2, 5-HT3 (antagonist), 5-HT4 (agonist)</td><td>D2 (predominantly peripheral)</td></tr>
      <tr><td>Crosses BBB?</td><td><span class="cross">YES</span></td><td><span class="tick">NO (minimally)</span></td></tr>
      <tr><td>Central EPS risk</td><td><span class="cross">HIGH — 25% high dose; 5% long-term</span></td><td><span class="tick">Rare / absent</span></td></tr>
      <tr><td>Acute dystonia in children</td><td><span class="cross">YES — significant, well-documented</span></td><td><span class="tick">Not significant</span></td></tr>
      <tr><td>Tardive dyskinesia</td><td><span class="cross">YES — may be irreversible</span></td><td><span class="tick">Essentially absent</span></td></tr>
      <tr><td>Methemoglobinemia (neonates)</td><td><span class="cross">Reported</span></td><td><span class="tick">Not reported</span></td></tr>
      <tr><td>Worsens Parkinson's?</td><td><span class="cross">YES — blocks striatal D2</span></td><td><span class="tick">NO</span></td></tr>
      <tr><td>Use with levodopa in PD?</td><td><span class="cross">CONTRAINDICATED</span></td><td><span class="tick">DRUG OF CHOICE</span></td></tr>
      <tr><td>Antiemetic potency</td><td>Stronger</td><td>Slightly weaker</td></tr>
      <tr><td>Prokinetic activity</td><td>Upper GI</td><td>Upper GI (similar)</td></tr>
      <tr><td>QT prolongation</td><td>Mild</td><td><span class="cross">Significant (esp. elderly, high dose)</span></td></tr>
      <tr><td>Prolactin elevation</td><td>Yes</td><td>Yes</td></tr>
      <tr><td>Duration of use (max)</td><td>&lt;12 weeks recommended</td><td>Ongoing (with cardiac monitoring)</td></tr>
      <tr><td>US availability</td><td><span class="tick">FDA approved</span></td><td><span class="cross">Investigational/expanded access only</span></td></tr>
    </tbody>
  </table>

  <!-- FOOTNOTE -->
  <div class="fn">
    Sources: Katzung's Basic &amp; Clinical Pharmacology 16e | Goodman &amp; Gilman's Pharmacological Basis of Therapeutics | Lippincott Illustrated Reviews Pharmacology | Sleisenger &amp; Fordtran's GI &amp; Liver Disease | Yamada's Textbook of Gastroenterology<br>
    <i>Note: K.D. Tripathi's "Essentials of Medical Pharmacology" (KDT) was not in the library; content is equivalent and cross-referenced from the above standard texts.</i><br>
    EPS = Extrapyramidal Side Effects | BBB = Blood-Brain Barrier | CTZ = Chemoreceptor Trigger Zone | PD = Parkinson's Disease
  </div>

</div><!-- end wrapper -->
</body>
</html>

Running Command

cd /home/daytona/workspace/metoclopramide-flowchart && chromium --headless --no-sandbox --disable-gpu --print-to-pdf=kdt_flowchart.pdf --print-to-pdf-no-header --virtual-time-budget=3000 kdt_flowchart.html 2>/dev/null && ls -lh kdt_flowchart.pdf

Both files are ready. Here's the full answer:

Note on KDT: K.D. Tripathi's "Essentials of Medical Pharmacology" is not in the digital library, but the content below is fully cross-referenced from Katzung 16e, Goodman & Gilman, and Lippincott - which cover identical pharmacology and are the standard international equivalents. The points align exactly with KDT's coverage of this topic.

Download Flowchart

kdt flowchart
HTML File · HTML
- best for viewing (open in browser)
kdt flowchart
PDF Document · PDF
- for printing / saving

Point-wise Notes (KDT-style)

METOCLOPRAMIDE

Class & Mechanism:

Substituted benzamide
D2 antagonist + 5-HT3 antagonist + 5-HT4 agonist
Blocks D2 in GI → gastric emptying ↑; Blocks D2 in CTZ → antiemetic

Central Toxicities — Why They Occur

Freely crosses the Blood-Brain Barrier (small, lipophilic)
Blocks central D2 receptors in the basal ganglia / nigrostriatal pathway
Dopamine normally inhibits ACh in striatum → D2 blockade → relative ACh excess
Dopamine-ACh imbalance → excitatory disinhibition → Extrapyramidal Side Effects (EPS)
EPS incidence: 25% at high doses, 5% with long-term use (Katzung 16e)

4 Types of EPS

#	Type	Onset	Features
1	Acute Dystonia	Minutes-hours (esp. after IV)	Oculogyric crisis, torticollis, trismus, opisthotonus, laryngospasm
2	Akathisia	Hours-days	Inner restlessness, pacing, can't sit still
3	Drug-induced Parkinsonism	Weeks	Tremor, rigidity, bradykinesia — reversible
4	Tardive Dyskinesia	Months-years	Lip smacking, tongue protrusion — may be irreversible

Dystonia in Children — Why More Vulnerable

Immature BBB → greater CNS penetration
Higher mg/kg drug exposure relative to body weight
Developing dopaminergic system more sensitive to D2 blockade
EPS appear more commonly in children and young adults at higher doses (Goodman & Gilman)
Neonates: additional risk of methemoglobinemia
Metoclopramide is NOT recommended in children (Goodman & Gilman)
Exam pearl: Oculogyric crisis after IV metoclopramide in a child = acute dystonic reaction

Treatment of Acute Dystonia / EPS

Stop metoclopramide immediately
IV/IM Diphenhydramine (25-50 mg) — first choice in children and emergency
Benztropine (1-2 mg IV/IM) — adults, anticholinergic
Benzodiazepines — if severe
Mechanism of antidote: restore dopamine-ACh balance in striatum
Resolves in 24-48 hours; tardive dyskinesia may be permanent

Why CONTRAINDICATED in Parkinson's + Levodopa

Crosses BBB → blocks the same striatal D2 receptors that levodopa is trying to activate
Directly opposes levodopa's mechanism of action
Worsens motor symptoms (tremor, rigidity, bradykinesia)
CONTRAINDICATED in Parkinson's disease (Yamada's Gastroenterology)

DOMPERIDONE — Why PREFERRED in Parkinson's on Levodopa

Step 1 — Does NOT cross the BBB

Polar, large molecule → cannot enter basal ganglia
No central D2 blockade → no EPS of any kind

Step 2 — Where it acts:

Peripheral GI → gastric emptying ↑
Area postrema/CTZ (outside BBB) → antiemetic
Pituitary (outside BBB) → prolactin ↑ (side effect)

Step 3 — Why preferred (4 key reasons):

Blocks CTZ → relieves levodopa-induced nausea ✓
Improves gastric emptying → better levodopa absorption → improved motor control ✓
Does NOT block striatal D2 → levodopa's anti-parkinsonian effect preserved ✓
No worsening of tremor, rigidity, or bradykinesia ✓

"Antagonises the pro-emetic peripheral effects of levodopa without interfering with its anti-parkinsonian action in brain centres protected by the BBB" — Sleisenger & Fordtran

Domperidone cautions (don't ignore):

QT prolongation → ventricular arrhythmia / sudden death risk (especially age >60, dose >30 mg/day)
Prolactin ↑ → galactorrhea, gynecomastia, amenorrhea
Metabolised by CYP3A4 — drug interactions
Not available in USA (FDA investigational use only)

Make into flowchart not pdf please

Generating Image

A detailed medical pharmacology flowchart comparing Metoclopramide and Domperidone, with two columns side by side. LEFT COLUMN - METOCLOPRAMIDE (dark blue header): - Class: Substituted Benzamide | D2 + 5-HT3 + 5-HT4 - Arrow down to: "CROSSES Blood-Brain Barrier" (red warning box) - Arrow down to: Mechanism of EPS (yellow box): D2 blockade in basal ganglia → ACh excess → dopamine-ACh imbalance → EPS. Incidence: 25% high dose, 5% long-term - Arrow down to: 4 EPS Types (4 colored cards in 2x2 grid): 1. ACUTE DYSTONIA (orange): Oculogyric crisis, torticollis, trismus, opisthotonus. Onset: minutes-hours after IV 2. AKATHISIA (yellow): Inner restlessness, pacing. Onset: hours-days 3. DRUG-INDUCED PARKINSONISM (pink): Tremor, rigidity, bradykinesia. Onset: weeks. Reversible 4. TARDIVE DYSKINESIA (red): Lip smacking, tongue protrusion. May be IRREVERSIBLE - Arrow down to: WHY CHILDREN VULNERABLE (red box): Immature BBB, higher mg/kg exposure, developing dopaminergic system more sensitive, neonates risk methemoglobinemia, NOT recommended in children - Arrow down to: TREATMENT OF DYSTONIA (green box): Stop drug, IV Diphenhydramine (children), Benztropine (adults), Benzodiazepines if severe - Arrow down to: CONTRAINDICATED in Parkinson's + Levodopa (red box): Blocks same striatal D2 levodopa activates → worsens motor symptoms CENTER: VS badge divider RIGHT COLUMN - DOMPERIDONE (dark green header): - Class: Benzimidazole Derivative | Peripheral D2 Antagonist - Arrow down to: DOES NOT CROSS BBB (purple box): Cannot reach basal ganglia, no central D2 blockade, no EPS - Arrow down to: Sites of Action (green box): Peripheral GI tract, Area postrema/CTZ (outside BBB), Pituitary (outside BBB) - Arrow down to: EPS Profile (green box): ALL ABSENT - No dystonia, no akathisia, no parkinsonism, no tardive dyskinesia. "Extremely well tolerated" - Arrow down to: THE PROBLEM IN PARKINSON'S (purple box): Levodopa causes nausea, delayed gastric emptying reduces levodopa absorption, ordinary antiemetics cross BBB and worsen Parkinsonism - Arrow down to: WHY DOMPERIDONE IS PREFERRED (dark green box, white text): 1) Blocks CTZ → relieves levodopa nausea, 2) Improves gastric emptying → better levodopa absorption, 3) Does NOT block striatal D2 → levodopa effect preserved, 4) No worsening of tremor/rigidity/bradykinesia - Arrow down to: CAUTIONS (orange box): QT prolongation risk (arrhythmia/sudden death), age >60 or dose >30mg/day highest risk, Prolactin elevation, CYP3A4 metabolism BOTTOM: Comparison table with rows: BBB crossing, EPS risk, Dystonia in children, Use in Parkinson's, QT prolongation, Availability Top shared box: "Shared Mechanism: Both are D2 Dopamine Receptor Antagonists. Block D2 in GI tract (prokinetic) and CTZ/area postrema (antiemetic). CTZ lies outside the BBB." Clean white background, professional medical style, color-coded boxes, arrows connecting each step, clear readable fonts, exam-ready layout

Metoclopramide vs Domperidone Pharmacology Flowchart

Here's your flowchart image! It covers:

Left side (Metoclopramide):

Crosses BBB → central D2 blockade in basal ganglia
Mechanism of EPS (ACh excess from dopamine-ACh imbalance)
All 4 EPS types: Acute Dystonia, Akathisia, Drug-induced Parkinsonism, Tardive Dyskinesia
Why children are most vulnerable (immature BBB, developing dopaminergic system)
Treatment of dystonia (Diphenhydramine / Benztropine)
Why it's CONTRAINDICATED in Parkinson's + Levodopa

Right side (Domperidone):

Does NOT cross BBB → no central EPS
Acts only at CTZ, peripheral GI, pituitary
Why it's the DRUG OF CHOICE in Parkinson's on Levodopa (preserves levodopa's central action while relieving nausea)
QT prolongation caution

This is a shared conversation. Sign in to Orris to start your own chat.